Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01AI155315 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Ifakara Health Institute | OTHER |
| Swiss Tropical & Public Health Institute | OTHER |
Not provided
Not provided
Not provided
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
This is a 3-arm open-label randomized control trial of 600 children aged 6 months to 10 years in Tanzania, where transmission is low and a high proportion of infections are low-density. Standard of care based on passive case detection (PCD) using rapid diagnostic test (control arm) will be compared to two different approaches to detect and treat P. falciparum LMI: active case detection using molecular testing (ACDm) and PCD using molecular testing (PCDm). Aims are:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Case Detection using molecular testing (ACDm) | Experimental | Per standard of care, children will receive passive case detection (PCD) using rapid diagnostic test (RDT) if they present with fever. Children will receive malaria active case detection (ACD) using RDT and qPCR (quantitative polymerase chain reaction) three times yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. |
|
| Passive Case Detection using molecular testing (PCDm) | Experimental | Children who present with fever will receive PCD using RDT and qPCR with treatment using AL if RDT or qPCR positive. Per standard of care, children will not receive malaria ACD. |
|
| Standard passive case detection (PCD) | Active Comparator | Per standard of care, children will receive PCD using RDT. Per standard of care, children will not receive malaria ACD. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active case detection using molecular testing (ACDm) | Other | In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of all-cause sick visits | Number of sick visits to health facility per person time, excluding planned admissions for medical care, elective surgery, and trauma. | 24-30 months from enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of anemia | Proportion of routine Hb measurements that are low (<11 g/dL) or moderate-severe low (<8 g/dL) | 24-30 months from enrollment |
| Prevalence of underweight status | Prevalence of underweight status will be defined as the percentage of participants with low weight for age z-scores of less than -2. The World Health Organization (WHO) anthropometric indices will be utilized for standards. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michelle Hsiang, MD, MSc | University of California, San Francisco | Principal Investigator |
| Ally Olotu, MD, PhD | Ifakara Health Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kiwangwa and Fukayosi clinics | Bagamoyo | Tanzania |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38538037 | Derived | Jebiwott S, Gutapaka N, Sumari D, Loss G, Athuman T, Nyandele JP, Cummins H, Chemba M, Benjamin-Chung J, Gangar P, Wu X, Smith J, Chen I, Dorsey G, Fink G, Olotu A, Hsiang M. Child Health and Infection with Low Density (CHILD) malaria: a protocol for a randomised controlled trial to assess the long-term health and socioeconomic impacts of testing and treating low-density malaria infection among children in Tanzania. BMJ Open. 2024 Mar 27;14(3):e082227. doi: 10.1136/bmjopen-2023-082227. |
Not provided
Not provided
Summary results information will be submitted to ClinicalTrials.gov within 12 months of completion of follow-up of all study participants. After completion of the clinical trial, un-blinding will be performed, and results will be disseminated widely by presentation at international scientific meetings, in reports and policy meetings for local, regional, and global stakeholders, and in publications in peer-reviewed journals. Upon completion of planned analyses and publication of the main trial results, data will be made available for research purposes to other individuals in the scientific community upon request to the PI and Consortium PIs. Informed consent documents for the study will include a specific statement relating to posting and sharing of study information at ClinicalTrials.gov, and in presentations, reports, and publications, and that no individual identities will ever be used in these materials and forums.
Upon completion of analysis and publication of main trial results
Request and approval of PIs Planned analyses completed and main trial results published
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form: Parent/Guardian consent for minor | Apr 28, 2025 | Jan 27, 2026 | ICF_000.pdf |
| ICF | No | No | Yes | Informed Consent Form: Assent form for minors | Apr 28, 2025 | Jan 27, 2026 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D016778 | Malaria, Falciparum |
| D008288 | Malaria |
| D000088562 | Persistent Infection |
| D058345 | Asymptomatic Infections |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
| Stanford University |
| OTHER |
| Chan Zuckerberg Biohub | OTHER |
Individual randomized controlled trial
Not provided
Not provided
This will be an open label randomized controlled trial. Participants and personnel administering the intervention will be unblinded. Assessment of the primary outcome will be unblinded. Assessment of several secondary outcomes will be blinded as feasible.
Not provided
| Passive case detection using molecular testing (PCDm) | Other | With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive. |
|
| Control (standard of care) | Other | With fevers, participants will receive standard PCD using RDT with treatment using AL if positive. |
|
| 24-30 months from enrollment |
| Prevalence of stunting | Prevalence of stunting will be defined as the percentage of participants with low height for age z-scores of less than -2. The World Health Organization (WHO) anthropometric indices will be utilized for standards. | 24-30 months from enrollment |
| Prevalence of wasting | Prevalence of wasting will be defined as the percentage of participants with low weight for height z-scores of less than -2. The World Health Organization (WHO) anthropometric indices will be utilized for standards. | 24-30 months from enrollment |
| Prevalence of malnutrition | Prevalence of malnutrition will be defined as the percentage of participants with a z-score of -3 to -2 indicating moderate malnutrition or a z-score of less than -3 indicating severe malnutrition in any of the following: weight for age, height for age, or weight for height. | 24-30 months from enrollment |
| Prevalence of vomiting following administration of study drugs | Vomiting immediately or within 30minutes following administration of study drugs and measures of non-adherence. | 24-30 months from enrollment |
| All-cause fever episodes | Number of fever episodes (reported fever in the past 48hrs and/or axillary temperature of ≥37.5°C) per person time | 24-30 months from enrollment |
| Incidence of clinical symptoms | Number of days with overall symptoms reported as moderate (≥3 on a 5-point scale) per person time | 24-30 months from enrollment |
| Incidence of clinical malaria | New episodes of positive malaria test (with fever or other clinical symptoms) per person time | 24-30 months from enrollment |
| Proportion of fever episodes with clinical failure | Proportion of fever episodes that lead to clinical failure, defined as persistent or worsening symptoms assessed 7 and 28 days after initial evaluation. | 24-30 months from enrollment |
| Prevalence of parasitemia | Proportion of routine samples with parasites detected by microscopy or quantitative polymerase chain reaction (qPCR). | 24-30 months from enrollment |
| Incidence in antibiotics prescribed | Number of antibiotic regimens prescribed per person time | 24-30 months from enrollment |
| Cognitive ability among children 0-3.4 years of age on the Global Scales of Early Development (GSED) | GSED is a validated instrument that measures population-level early childhood development. The tool measures children's early skills and behaviors in four primary domains: motor, cognitive, language, and social-emotional development.Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance. | 24-30 months from enrollment |
| Cognitive ability among children 3.5-5 years of age on the International Development and Early Learning Assessment (IDELA) | The IDELA is a validated, global tool that uses direct child assessment to measure early learning and development across 4 core domains (Emergent Literacy, Emergent Numeracy, Motor, Social-emotional). Scores range from 0-100% as a percentage of correct tasks averaged across the 4 domains. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance. | 24-30 months from enrollment |
| Cognitive ability among children 6-12 years of age on the East Africa Neurodevelopment Assessment Tool | The East African Neurodevelopment Assessment Tool is a locally adapted modification of the Kaufman Brief Intelligence Test 2nd Ed. The test assesses 3 core metrics including general intelligence, executive function, literacy skills - in addition to behavioral and emotional development. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance. | 24-30 months from enrollment |
| Sustained attention among children 5-8 years of age on the Pencil Tapping Test | The pencil tapping test is one of the tasks in the Preschool Self-Regulation Assessment (PSRA) and is used to assess inhibitory control in younger children. The child and an assessor have pencils, and child is instructed to tap one/two times(s) depending on what assessor does, with the number of correct responses scored. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance. | 24-30 months from enrollment |
| Sustained attention among children 9-12 years of age on the Code Transmission Test, a local adaptation of the Test of Everyday Attention for Children(TEA-Ch) | Code transmission test is a sub-test of Test of Everyday Attention for Children (TEA-Ch) used for assessment of sustained attention in children. In the test, the child must remember spoken digits, and remember the digit that comes before sequence of numbers. Child is scored on completed and correct answers. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance. | 24-30 months from enrollment |
| Incidence of school absenteeism | The number of days of school absenteeism for any reason including illness. | 24-30 months from enrollment |
| School performance | School performance will be defined as the incidence of school advancement to the next grade. | 24-30 months from enrollment |
| Socioeconomic costs to participant | Estimated long-term income loss due to impaired early childhood development | 24-30 months from enrollment |
| Socioeconomic costs to family | Total caregiver-reported costs of sick visits and transport to sick visits plus estimated loss of income from number of days of caregiver work absenteeism. | 24-30 months from enrollment |
| Socioeconomic costs to health system | Estimated costs of testing and treatment for caregiver-reported number of sick visits. | 24-30 months from enrollment |
| Cost effectiveness | Cost per outcome averted (e.g., per sick visit averted, per disability adjusted life years (DALYs), and per economic dollar saved, etc.) | 24-30 months from enrollment |
| Prevalence of systemic inflammation | Proportion of sick visits with elevated elevated C-reactive pep-tide (CRP) | 24-30 months from enrollment |
| Proportion with antimalarial antibodies against P.falciparum | Percentage of patients with antimalarial antibodies | 24-30 months from enrollment |
| Proportion with biomarkers of inflammation | Percentage of patients with elevated cytokines | 24-30 months from enrollment |
| Proportion with general antibody responses to vaccines | Percentage of patients with vaccine antibodies | 24-30 months from enrollment |
| Proportion with general antibody responses to common pathogens | Percentage of patients with common pathogen antibodies | 24-30 months from enrollment |
| Incidence of adverse events (AEs) | Number of AEs per person time. AEs will be considered as any grade 3-4 AE or serious adverse event (SAE); individual AEs; or AEs related to study drugs. | 24-30 months from enrollment |
| Incidence of wasting | Incidence proportion of wasting will be defined for each age range of measurement. It is defined as the proportion of children not wasted at the start of the period who became wasted during the age period (the proportion of children who had the onset of new episodes during the period). Incident wasting episodes are defined as a change in weight-for-length z-scores from above -2 Z in the prior measurement to below -2 Z in the current measurement. We will define incident severe wasting analogously using a -3 Z cutoff. We will assume a 60-day washout period before a new wasting episode could occur. | 24-30 months from enrollment |
| Incidence of stunting | Incidence proportion of stunting will be defined for each age range of measurement. It is defined as the proportion of children not stunted at the start of the period who became stunted during the age period. Incident stunting episodes will be defined as a change in length-for-age z-scores from above -2 Z in the prior measurement to below -2 Z in the current measurement. We will define incident severe stunting analogously using a -3 Z cutoff. | 24-30 months from enrollment |
| D000079426 |
| Vector Borne Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D058070 | Asymptomatic Diseases |